BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 9, 2003
View Archived Issues
Three series of 5-HT2C agonists for schizophrenia and obesity claimed by Wyeth
Read More
New agents for Flaviviridae infections covered by ViroPharma patent
Read More
Nippon Shinyaku presents novel antipruritic agents
Read More
Sumitomo researchers design novel ACAT inhibitors for arteriosclerosis therapy
Read More
New MMP-13 inhibitors identified at Takeda
Read More
Yamanouchi scientists prepare and test new glycogen phosphorylase inhibitors
Read More
Antitumor effects of the HLA-DR-specific MAb 1D09C3 shown in vitro and in vivo
Read More
CGP-76030 inhibits proliferation of imatinib-resistant, Bcr/Abl-transformed murine bone marrow cells
Read More
Enhanced apoptosis with LAQ-824 and Apo2L/TRAIL cotreatment
Read More
CC-5079 induces NF-B-independent apoptosis of hematopoietic cancer cells
Read More
Potent in vitro effects of OSW-1 against human leukemia cells
Read More
U.S. launch of Risperdal Consta
Read More
Allos completes RSR-13 NDA filing
Read More
Treatment commences in pivotal European phase II trial of clofarabine for ALL
Read More
Collegium and Endo to develop abuse-resistant opioids
Read More
Discovery Partners and Allergan enter lead discovery collaboration
Read More
PDE4 inhibitor AWD-12-281 progresses through the clinic
Read More
ETC-1001 safe and well tolerated in phase I study
Read More
GBTherapeutics cleared to begin Canadian phase Ia trial of GT-1061
Read More
Emory University, GSK and NIMH team up to tackle depression and mood disorders
Read More
Cipralex approved in select European countries for social anxiety disorder
Read More
Immunomedics updates progress of key antibody product candidates
Read More
New site added to international phase II study of Litx
Read More
Merck & Co. and Actelion join forces to develop renin inhibitors
Read More
MLN-2704 granted fast track designation
Read More
First NO compound from Merck/NitroMed partnership enters clinical testing
Read More
Certican completes European mutual recognition procedure
Read More
Phytopharm cleared to commence phase I testing of PYM-50018 for ALS
Read More